Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease.

ABSTRACT:

Background

Blood-based AD biomarkers such as plasma P-tau217 are increasingly used in clinical trials as a screening tool.

Objectives

To assess the utility of an electrochemiluminescence (ECL) immunoassay in predicting brain amyloid PET status in cognitively unimpaired individuals.

Setting

Plasma samples collected at baseline, week 12, and week 240 or endpoint originated from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial and the companion Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) study.

Participants

Both A4 and LEARN enrolled eligible cognitively unimpaired persons 65 to 85 years. Individuals with elevated brain amyloid PET levels were eligible for the A4 Study, while those without elevated brain amyloid P

SUBMITTER: Rissman RA 

PROVIDER: S-EPMC11266279 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature